Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability

Core Viewpoint - Drugmakers are preparing for potential levies and are proactively committing to invest billions in domestic manufacturing [1] Group 1 - Drugmakers are bracing for upcoming levies [1] - Companies are seeking to get ahead of these levies by pledging significant investments [1] - The focus of these investments is on enhancing domestic manufacturing capabilities [1]